These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35281080)

  • 41. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognosis and immune infiltration analysis of endoplasmic reticulum stress-related genes in bladder urothelial carcinoma.
    Wang Y; Zhu H; Wang X
    Front Genet; 2022; 13():965100. PubMed ID: 36186448
    [No Abstract]   [Full Text] [Related]  

  • 43. High expression of
    Lin B; Zhang T; Ye X; Yang H
    Oncol Lett; 2020 Sep; 20(3):2840-2854. PubMed ID: 32782602
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunological significance of alternative splicing prognostic signatures for bladder cancer.
    Li X; Yang L; Huang W; Jia B; Lai Y
    Heliyon; 2022 Feb; 8(2):e08994. PubMed ID: 35243106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer.
    Zhou L; Xu G; Huang F; Chen W; Zhang J; Tang Y
    BMC Med Genomics; 2023 Apr; 16(1):88. PubMed ID: 37118734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer.
    Zhang LH; Li LQ; Zhan YH; Zhu ZW; Zhang XP
    Front Mol Biosci; 2021; 8():607090. PubMed ID: 33937319
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine.
    Sun Z; Jing C; Zhan H; Guo X; Suo N; Kong F; Tao W; Xiao C; Hu D; Wang H; Jiang S
    Front Immunol; 2023; 14():1097472. PubMed ID: 36761744
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New Prognostic Gene Signature and Immune Escape Mechanisms of Bladder Cancer.
    Jiang Y; Zeng Z; Xiong S; Jiang M; Huang G; Zhang C; Xi X
    Front Cell Dev Biol; 2022; 10():775417. PubMed ID: 35646934
    [No Abstract]   [Full Text] [Related]  

  • 49.
    Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H
    Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comprehensive Investigation of Genes Associated with Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma.
    Mi Y; Wang X
    J Environ Pathol Toxicol Oncol; 2022; 41(3):1-12. PubMed ID: 35993952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Classification of colorectal carcinoma subtypes based on ferroptosis-associated molecular markers.
    Yue Q; Zhang Y; Wang F; Cao F; Duan X; Bai J
    World J Surg Oncol; 2022 Apr; 20(1):117. PubMed ID: 35410338
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PGM1 and ENO1 Promote the Malignant Progression of Bladder Cancer via Comprehensive Analysis of the m6A Signature and Tumor Immune Infiltration.
    Zhao J; Huang S; Tan D; Yang K; Chen M; Jia X; Mao X
    J Oncol; 2022; 2022():8581805. PubMed ID: 35251177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Multiomics Profiling Based on Online Database Revealed Prognostic Biomarkers of BLCA.
    Li H; Chen S; Mi H
    Biomed Res Int; 2022; 2022():2449449. PubMed ID: 35669725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer.
    Zhang X; Zhang Y; Zhao L; Wang J; Li J; Wang X; Zhang M; Hu X
    Front Immunol; 2022; 13():1014638. PubMed ID: 36569935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification and validation of prognostic signature genes of bladder cancer by integrating methylation and transcriptomic analysis.
    Chatterjee D; Mou SI; Sultana T; Hosen MI; Faruk MO
    Sci Rep; 2024 Jan; 14(1):368. PubMed ID: 38172584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer.
    Zhu K; Deng W; Deng H; Liu X; Wang G; Fu B
    PPAR Res; 2021; 2021():7056506. PubMed ID: 35027921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
    Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
    Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer.
    Fu Y; Sun S; Bi J; Kong C; Yin L
    BMC Cancer; 2021 Jul; 21(1):810. PubMed ID: 34266411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of Immune-Related Subtypes and Construction of a Novel Prognostic Model for Bladder Urothelial Cancer.
    Zhang J; Huang C; Yang R; Wang X; Fang B; Mi J; Yuan H; Mo Z; Sun Y
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36421685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.
    Zhang Z; Yu Y; Li P; Wang M; Jiao W; Liang Y; Niu H
    Front Immunol; 2022; 13():954616. PubMed ID: 35958586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.